Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 19/20 | 0.73 |
| ▸ | HRH1 | P35367 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10248179 | 0.85 | HRH3 (1.00) | HRH3HRH1 | |
| SCHEMBL4394162 | 0.84 | HRH3 (0.75) | HRH3HRH1 | |
| SCHEMBL4391462 | 0.82 | HRH3 (0.73) | HRH3HRH1 | |
| SCHEMBL4400002 | 0.77 | HRH3 (0.47) | HRH3HRH1 | |
| SCHEMBL4400094 | 0.77 | HRH3 (0.47) | HRH3HRH1 | |
| SCHEMBL4392910 | 0.74 | HRH3 (0.71) | HRH3 | |
| SCHEMBL4396046 | 0.74 | HRH3 (0.72) | HRH3HRH1 | |
| SCHEMBL4398179 | 0.74 | HRH3 (0.60) | HRH3 | |
| SCHEMBL4393279 | 0.73 | HRH3 (0.73) | HRH3 | |
| SCHEMBL4398407 | 0.73 | HRH3 (0.71) | HRH3HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306052-A1 | INDENYL DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | GLAXO GROUP LIMITED | 2009-12-10 | — | — | US | claimed |
| US-20090306052-A1 | INDENYL DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | GLAXO GROUP LIMITED | 2009-12-10 | — | — | US | disclosed |
| US-20090306052-A1 | INDENYL DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | GLAXO GROUP LIMITED | 2009-12-10 | — | — | US | disclosed |
| US-20090306052-A1 | INDENYL DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | GLAXO GROUP LIMITED | 2009-12-10 | — | — | US | disclosed |
| EP-1833796-A1 | INDENYL DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | GLAXO GROUP LIMITED (GB) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006061193-A1 | INDENYL DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306052-A1 | INDENYL DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NLN, INMT, INA | HRH3 2097/4885HRH1 2957/4885HTR2A 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.